Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cosimo Durante

Showing results (141-150 of 175) with videos related to

Pageof 18
Sort By:
Endocrine|February 13, 2020
Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinomaRosa Falcone, Marialuisa Sponziello, Raffella Carletti, et al.
Endocrine|March 25, 2020
Correction to: Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinomaRosa Falcone, Marialuisa Sponziello, Raffella Carletti, et al.
Thyroid : Official Journal of the American Thyroid Association|September 10, 2020
Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid CancerCarlotta Giani, Laura Valerio, Alberto Bongiovanni, et al.
Thyroid : Official Journal of the American Thyroid Association|April 8, 2014
Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodiesCosimo Durante, Sara Tognini, Teresa Montesano, et al.
European Thyroid Journal|April 13, 2026
Real-world efficacy of Lenvatinib/Pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centersEdoardo Talpacci, Manuela Macera, Giulia Maida, et al.
Cancers|January 23, 2020
Does the Site of Origin of the Microcarcinoma with Respect to the Thyroid Surface Matter? A Multicenter Pathologic and Clinical Study for Risk StratificationGiovanni Tallini, Antonio De Leo, Andrea Repaci, et al.
Endocrine-Related Cancer|July 13, 2016
RET mutation and increased angiogenesis in medullary thyroid carcinomasAntonella Verrienti, Giovanni Tallini, Chiara Colato, et al.
Human Mutation|December 9, 2017
Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancerMarialuisa Sponziello, Silvia Benvenuti, Alessandra Gentile, et al.
Journal of Clinical Medicine|April 9, 2024
<i>Drawing as a Way of Knowing</i>: How a Mapping Model Assists Preoperative Evaluation of Patients with Thyroid CarcinomaMarco Biffoni, Giorgio Grani, Rossella Melcarne, et al.
The Journal of Clinical Endocrinology and Metabolism|July 28, 2010
Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomasCosimo Durante, Marco Attard, Massimo Torlontano, et al.
Pageof 18

Showing results (141-150 of 175) with videos related to

Sort By:
Pageof 18
Endocrine|February 13, 2020
Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinomaRosa Falcone, Marialuisa Sponziello, Raffella Carletti, et al.
Endocrine|March 25, 2020
Correction to: Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinomaRosa Falcone, Marialuisa Sponziello, Raffella Carletti, et al.
Thyroid : Official Journal of the American Thyroid Association|September 10, 2020
Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid CancerCarlotta Giani, Laura Valerio, Alberto Bongiovanni, et al.
Thyroid : Official Journal of the American Thyroid Association|April 8, 2014
Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodiesCosimo Durante, Sara Tognini, Teresa Montesano, et al.
European Thyroid Journal|April 13, 2026
Real-world efficacy of Lenvatinib/Pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centersEdoardo Talpacci, Manuela Macera, Giulia Maida, et al.
Cancers|January 23, 2020
Does the Site of Origin of the Microcarcinoma with Respect to the Thyroid Surface Matter? A Multicenter Pathologic and Clinical Study for Risk StratificationGiovanni Tallini, Antonio De Leo, Andrea Repaci, et al.
Endocrine-Related Cancer|July 13, 2016
RET mutation and increased angiogenesis in medullary thyroid carcinomasAntonella Verrienti, Giovanni Tallini, Chiara Colato, et al.
Human Mutation|December 9, 2017
Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancerMarialuisa Sponziello, Silvia Benvenuti, Alessandra Gentile, et al.
Journal of Clinical Medicine|April 9, 2024
<i>Drawing as a Way of Knowing</i>: How a Mapping Model Assists Preoperative Evaluation of Patients with Thyroid CarcinomaMarco Biffoni, Giorgio Grani, Rossella Melcarne, et al.
The Journal of Clinical Endocrinology and Metabolism|July 28, 2010
Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomasCosimo Durante, Marco Attard, Massimo Torlontano, et al.
Pageof 18